文献速递炎症性肠病

日本真实世界多中心研究:三种Janus激酶抑制剂治疗溃疡性结肠炎的疗效与安全性比较

Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A Real-World Multicentre Study in Japan.
PubMed 文献 · Aliment Pharmacol Ther · 2024-11-22

该多中心回顾性研究纳入228例乌帕替尼、215例非戈替尼和159例托法替尼治疗的溃疡性结肠炎患者,采用倾向评分匹配比较疗效与安全性。最近随访时临床缓解率分别为72.8%、50.6%和45.8%,乌帕替尼疗效更高且停药风险更低,但痤疮风险显著。作者认为可考虑先使用非戈替尼或托法替尼,再使用乌帕替尼。

要点

  • 最近随访临床缓解率:乌帕替尼72.8%、非戈替尼50.6%、托法替尼45.8%。
  • 乌帕替尼疗效更高、停药风险更低,但痤疮风险显著。
  • 作者认为可考虑先使用非戈替尼或托法替尼,再使用乌帕替尼。

核心结论

  • 考虑到乌帕替尼即使在难治性溃疡性结肠炎患者中疗效也特别高,作者认为可考虑先使用非戈替尼或托法替尼作为初始JAK抑制剂,再使用乌帕替尼。

研究设计与样本

  • 多中心回顾性研究,纳入开始使用JAK抑制剂的溃疡性结肠炎患者,共228例乌帕替尼治疗患者(中位随访49周,IQR 25-72)、215例非戈替尼治疗患者(随访56周,IQR 17-82)和159例托法替尼治疗患者(随访112周,IQR 10-258)。
  • 采用倾向评分匹配创建三个配对队列:乌帕替尼 vs 非戈替尼、托法替尼 vs 非戈替尼、乌帕替尼 vs 托法替尼。
  • 主要结局为第10、26、58周及最近随访时的临床缓解。

主要发现

  • 最近随访时临床缓解率:乌帕替尼72.8%、非戈替尼50.6%、托法替尼45.8%。
  • 超过70%既往接受过其他生物制剂或JAK抑制剂治疗的患者使用乌帕替尼后达到临床缓解。
  • 多因素分析显示,既往先进治疗数量与非戈替尼和托法替尼的疗效呈负相关。
  • 比较分析显示,乌帕替尼治疗患者的疗效高于其他JAK抑制剂治疗患者,且停药风险更低。
  • 乌帕替尼有显著的痤疮风险。

临床怎么用

  • 作者认为,考虑到乌帕替尼即使在难治性溃疡性结肠炎患者中疗效也特别高,可考虑先使用非戈替尼或托法替尼作为初始JAK抑制剂,再使用乌帕替尼。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Three Janus kinase (JAK) inhibitors are approved for ulcerative colitis (UC) in Japan. AIM: To compare the real-world efficacy and safety of these three JAK inhibitors in UC. METHODS: This was a multicentre, retrospective study of patients with UC started on JAK inhibitors. The primary outcome was clinical remission at 10, 26 and 58 weeks, and at the most recent follow-up. To compare the efficacy and safety among the JAK inhibitors, we created three matched cohorts (upadacitinib vs. filgotinib, tofacitinib vs. filgotinib and upadacitinib vs. tofacitinib) using propensity score matching. RESULTS: We identified 228 upadacitinib-treated patients (median follow-up 49 weeks; IQR 25-72), 215 filgotinib-treated patients (follow-up 56 weeks; IQR 17-82) and 159 tofacitinib-treated patients (follow-up 112 weeks; IQR 10-258). Clinical remission rates for upadacitinib, filgotinib and tofacitinib at the most recent follow-up were 72.8%, 50.6% and 45.8%, respectively. Over 70% of the patients previously treated with other biologics or JAK inhibitors achieved clinical remission with upadacitinib. On multivariate analysis, the number of previous advanced therapies was inversely associated with the efficacy of filgotinib and tofacitinib. Comparative analysis showed that upadacitinib-treated patients had higher efficacy and lower risk of discontinuation than patients treated with other JAK inhibitors. However, upadacitinib had a significant risk of acne. CONCLUSIONS: Considering the particularly high efficacy of upadacitinib, even in patients with refractory UC, filgotinib or tofacitinib may be considered as an upfront JAK inhibitor before using upadacitinib.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Akiyama S, Shimizu H, Tamura A, et al. Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A Real-World Multicentre Study in Japan. Aliment Pharmacol Ther. 2024. PMID: 39578704. doi:10.1111/apt.18406

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。